Key TakeawaysElevance Health (ELV) reported a Q4 2025 adjusted EPS of $3.33, exceeding estimates of $3.10, but missed on operating revenue and provided a 2026 adjusted EPS outlook of at least $25.50, below analyst expectations of $26.99.Danaher (DHR) delivered a strong Q4 2025 performance, with sales reaching $6.84 billion (above estimates of $6.79 billion) and adjusted EPS of $2.23 (beating estimates of $2.16), while its 2026 adjusted EPS guidance of $8.35 to $8.50 aligned with estimates.RTX (RTX) received ...